All In Biotech

Drug Trial Radar · NCT07751744

Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma

A Phase 1/2, Multicenter, Open-Label, Dose-Escalation/Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered JBI-778 in Patients With Brain Metastasis, Leptomeningeal Disease, or High Grade Recurrent Glioma

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

113

Planned (sponsor's estimate)

Start

Apr 1, 2028

Primary completion

Mar 31, 2030

Study completion Mar 31, 2030

Sponsor

Lead sponsor
Jubilant Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Aug 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, multicenter, open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), cerebrospinal fluid penetration, and preliminary antitumor activity of orally administered JBI-778, a selective PRMT5 inhibitor, in patients with brain metastases, leptomeningeal disease, or recurrent high-grade glioma. The study consists of a dose-escalation phase to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), followed by expansion cohorts to evaluate preliminary efficacy at the RP2D.

Conditions

  • Brain Metastases From Solid Tumors
  • Leptomeningeal Disease
  • High Grade Glioma (HGG)
  • Glioblastoma (GBM)

Interventions

  • JBI-778Drug

    Drug: JBI-778 Oral capsule Strengths: 20 mg, 100 mg, 250 mg Starting dose: 40 mg daily Continuous once-daily administration in 21-day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 - Incidence of Dose Limiting Toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Phase 2 High-Grade Glioma Cohort: Objective Response Rate (ORR)Time frame: Up to 2 years
  3. Phase 2 Brain Metastases Cohort: Objective Response Rate (ORR)Time frame: Up to 2 years.
  4. Phase 2 Leptomeningeal Disease Cohort: Overall Survival (OS)Time frame: Up to 2 years.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.